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Abstract
Background: Ligand-dependent activation of the G-protein coupled receptor 119 (GPR119) lowers blood glucose
via glucose-dependent insulin secretion and intestinal glucagon-like peptide-1 production. However, the function of
GPR119 in cancer cells has not been studied.
Methods: GPR119 expression was assessed by real-time qPCR and immunohistochemistry in human breast cancer cell lines
and breast cancer tissues. Cell proliferation and cell cycle analyses were performed by Incucyte® live cell analysis system and
flow cutometry, respectively. Autophagy activity was estimeated by western blottings and LC3-GFP transfection.
Results:mRNA or protein expression of GPR119 was detected in 9 cancer cell lines and 19 tissue samples. Cotreatment with
GPR119 agonist (MBX-2982 or GSK1292263) significantly potentiated gefitinib-induced cell growth inhibition in gefitinib-
insensitive MCF-7 and MDA-MB-231 breast cancer cells. We observed that caspase-3/7 activity was enhanced with the
downregulation of Bcl-2 in MCF-7 cells exposed to MBX-2982. Gefitinib-induced autophagy is related with cancer cell
survival and chemoresistance. GPR119 agonists inhibit gefitinib-induced autophagosome formation in MCF-7 and MDA-MB-
231 cells. MBX-2982 also caused a metabolic shift to enhanced glycolysis accompanied by reduced mitochondrial oxidative
phosphorylation. MBX-2982 increased intracellular (~ 2.5 mM) and extracellular lactate (~ 20 mM) content. Gefitinib-mediated
autophagy was suppressed by 20 mM lactate in MCF-7 cells.
Conclusions: GPR119 agonists reduced mitochondrial OXPHOS and stimulated glycolysis in breast cancer cells, with
consequent overproduction of lactate that inhibited autophagosome formation. Because autophagy is crucial for the survival
of cancer cells exposed to TKIs, GPR119 agonists potentiated the anticancer effects of TKIs.
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Background
Anti-epidermal growth factor receptor (EGFR) therapy is
an effective way to inhibit proliferation of many cancer
types such as non–small cell lung cancer (NSCLC) and
colorectal cancer [1]. However, EGFR-tyrosine kinase in-
hibitor (TKI) alone or in combination therapy with pacli-
taxel or docetaxel had been used for breast cancer patients
in clinical trials, but both therapies failed [2]. Thus, it may
be necessary to investigate the chemoresistance mecha-
nism(s) to EGFR TKI for breast cancer patients.
Macroautophagy or autophagy is a lysosomal degradative
process that recycles cellular components and maintains
cell homeostasis [3]. In autophagy, double-membrane vesi-
cles (autophagosomes) sequestrate selected substrates and
fuse with lysosomes (autolysosomes). Autophagy dysfunc-
tion results in the accumulation of intracellular damaged
proteins, causing neurodegeneration or cardiac hypertrophy
[4]. The effect of autophagy activation on a cancer cell sur-
vival is controversial. Accelerated autophagy is believed to
be an anticancer mechanism for a variety of agents. Nur77
agonists induce autophagic cell death in melanoma cells
[5]. Rapamycin, an mTOR inhibitor, induces autophagic cell
death in MG63 osteosarcoma cells [6]. In contrast, autoph-
agy is actively involved in cancer cell resistance to
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anticancer agents through recycling of cellular energy
sources and components. For instance, treatment with
chloroquine, an autophagy flux inhibitor, overcomes
anti-estrogen resistance of MCF-7 cells [7]. Chloroquine
also enhanced a cytotoxicity of temozolomide in glioma
cells [8]. Thus, potential role of autophagy in cancer
chemotherapy remains elusive.
Lipid-sensing G-protein-coupled receptors (GPCRs)
are highly expressed in pancreatic β-cells and implicated
with metabolic symdroms [9]. Previous studies examined
the diverse functions of lipid-sensing receptors in the
development and progression of cancer. GPR120 is acti-
vated by ω-3 fatty acids and promotes tumor progression
and angiogenesis in prostate cancer [10, 11]. Activations
of GPR43 and GPR109A which sense short-chain fatty
acids suppress cell proliferation of colon cancer cells and
tumorigenesis of breast cancer cells [12, 13]. Oleic acid,
an endogenous ligand of GPR40, promotes the prolifera-
tion of breast cancer cells, but TAK-875, a synthetic lig-
and of GPR40, inhibits the tumor growth of melanoma
[14, 15]. GPR119 is activated by endogeneous oleoy-
lethanolamine(OEA) and mainly coupled to Gαs signal-
ing [9]. Although GPR119 is a promising target for type
II diabetes and fatty liver diseases [16], a role of GPR119
in cancer has not been studied. Here, we found that
GPR119 was ubiquitously expressed in human breast
cancer cell lines and tumor tissues. We investigated in
vitro and in vivo combination effects of GPR119 agonists
with TKIs in breast cancer and hepatoma cells, and clari-
fied the mechanistic basis for the anticancer effects of
GPR119 agonists, focusing on autophagy inhibition.
Methods
Cell culture
Breast cancer cell lines (MCF-7, MDA-MB-231 and
TamR-MCF-7) were cultured in Dulbecco’s modified Ea-
gle’s medium (DMEM) containing 10% fetal bovine
serum and 1% penicillin-streptomycin. MCF-10A was
cultured in media as described previously [17]. Other
breast cancer cell lines were cultured in RPMI1640
media. Hepatocellular carcinoma cell lines (HepG2 and
HepG2-X cells) were cultured in DMEM containing 10%
fetal bovine serum and 1% penicillin-streptomycin.
Antibodies and reagents
MBX-2982, GSK1292263, gefitinib and sorafenib were
obtained from Medchemexpress (Monmouth Junction,
NJ, USA). Chloroquine, 3-methyladenine (3-MA) and
other reagents were purchased from Sigma-Aldrich (St.
Louis, MI). Anti-GPR119 antibody was supplied from
Abcam (Cambridge, UK). Anti-monocarboxlyate trans-
porter (MCT) 1, anti-MCT2, anti-MCT4, anti-lactate
dehydrogenase (LDH) A, anti-LDHB antibodies were
purchased from Santa Cruz Biotechnology (Dallas, TX,
USA). Other antibodies including LC3B were supplied
from Cell Signaling Technology (Danvers, MA, USA).
GFP-LC3B plasmid were kindly donated from Dr. Kim J
(University of Florida, Gainesville, FL, USA).
Incucyte® live cell analysis system for the determination
of cell proliferation and caspase-3/7 activity
Cells were seeded in 96 well plate and real-time moni-
tored by Incucyte® system (Essenbio science, Ann Arbor,
MI, USA). Sets of images were acquired and analyzed by
Incucyte® basic software. Caspase3/7 activity in apoptotic
cells was visualized with Kinetic caspase 3/7 reagent
(cat.4440, Essenbio science). The half maximal inhibitory
concentration (IC50) values were calculated through
non-linear regression analysis using SigmaPlot ver. 12
(Systat Software Inc., San Jose, California, USA).
Western blot analysis
Cells were washed with cold phosphate-buffered saline
(PBS) and lysed in lysis buffer (150 mM Tris-Cl (pH.7.6),
10% NP-40, protease inhibitors and phosphatase inhibi-
tors) and centrifuged at 16000 g, 4 °C. The proteins were
separated in sodium dodecyl sulfate (SDS)-polyacryla-
mide gel electrophoresis (PAGE) and transferred to
nitrocellulose membrane. The membranes were incu-
bated with specific primary antibodies diluted in 5%
skim milk in Tween 20-containing PBS and correspond-
ing secondary antibodies.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
and quantitative real-time PCR (qPCR)
Total RNA was extracted using Trizol reagent (Invitrogen,
Carlsbad, CA, USA). cDNA was synthesized by reverse
transcriptase kit (iNtRON, Seoul, South Korea) and PCR
was performed using specific primers: human GPR119 F:
5’-CTCCCTCATCATTGCTACTAA-3′, R: 5’-ACAGCCA
GATTCAAGGTG-3′. GAPDH F: 5’-AGCCACATC
GCTCAGA CAC-3′, R: 5’-GCCCAATACGACCAAATC
C-3′. The SYBR Green qPCR amplification was conducted
with MiniOpticon real time PCR detection system
(Bio-Rad laboratories Inc., Hercules, CA, USA).
Immunohistochemistry
Forty-nine human breast cancer tissues were obtained
from Chungnam National University hospital (IRB ap-
proval #: CNUH 2015–03-001). Tissue sections were
processed from formalin-fixed paraffin-embedded tissue
samples according to previously described method [18].
Tissue sections were stained with anti-GPR119 or
anti-estrogen receptor α antibody as primary antibody and
images of tissue sections were taken by a bright-field mi-
croscopy. In statistics, the pearson’s correlation coefficient
between GPR119 and clinical pathology was calculated
from sigma plot.
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1H-NMR analysis for lactate and glucose determination
Cell lysates and media were dried using speed vacuum
concentrator and reconstructed in appropriate buffer
(2 mM Na2HPO4, 5 mM NaH2PO4, 0.025% trimethylsilyl
propionate in 99.9% D2O). Proton-NMR (1H-NMR)
spectroscopy was performed by Bruker 500 MHz spec-
trometer (Bruker Coperation, Billerica, MA, USA). Lac-
tate was also determined by lactate assay kit (Abcam,
Cambridge, UK). Sample preparation and protocols were
performed according to the manufacture’s instruction.
Xenograft analysis
Female Balb/c-nu mice were purchased from Raonbio
(Seoul, South Korea). Animal studies were performed ac-
cording to the regulation and an approval of Seoul Na-
tional University Institutional Animal Care and Use
Committee (Approval #: SNU-140106-1). Briefly,
five-week-old female BALB/c-nude mice were inoculated
with cancer cells in flank side. The mice were intraperi-
tonially injected with 17-β-estradiol (2 mg/kg/day). Gefi-
tinib (1 mg/kg/day, 5 times a week) and MBX-2982
(10 mg/kg/day, 5 times a week) were orally administered
to the mice for 40 days.
Transmission Electron microscopy (TEM)
Cells were fixed with karnovskys fixative and washed 3
times with 2 ml 0.05 M cacodylate buffer and post-fixed
with 2% osmium tetroxide for 2 h. After washing with
distilled water, cells were stained with 0.5% uranyl acet-
ate and dehydrated with a series of ethanol and propyl-
ene oxide. Cells were embeded in spurr’s resin and
polymerized at 70 °C. The blocks were trimmed to ultra-
thin section using an ultramicrotome (EM UC7, Leica,
Wetzlar, Germany) and observed with Transmission
Electron Microscope (JEM1010, JEOL, Tokyo, Japan).
siRNA transfection and shRNA infection
siGENOME SMARTpools systems for ATG7 (cat #
MQ-020112-01-0002) knockdown and scramble (cat #
D-001206-13-05) were purchased from Dharmacon (La-
fayette, CO). MCF-7 cells and HepG2 cells were trans-
fected with siRNA using FuGENE® HD Transfection
Reagent (Promega, Madison, WI, USA). shRNA lenti-
virus particles for GPR119 (cat # SHCLNV-NM_178471)
and Nontarget control (cat # SHV0002) were purchased
from Sigma-Aldrich. MCF-7 cell was incubated with
lentivirus particles and hexamidine bromide. Stable cell
lines were generated by puromycin treatment for more
than 2 weeks.
Mitochondria enrichment fraction isolation
Crude mitochondria were isolated by sucrose gradient
purification. Cells were seeded in 150 mm2 culture plate
and treated with MBX-2982 for 6 h. The cells were
washed 3 times with PBS, harvested with trypsin and sus-
pended in 1 ml NKM buffer (1 mM Tris-Cl, pH 7.4,
0.13 M NaCl, 5 mM KCl, 7.5 mM MgCl2). The cell mix-
ture was centrifuged and suspended in 0.6 ml
homogenization buffer (10 mM Tris-Cl, pH 6.7, 10 mM
KCl, 0.15 mM MgCl2) and homogenized using a pestle
and glass potter. The homogenate was mixed with 0.1 ml
2 M sucrose and centrifuged at 1200 g for 5 min and re-
peated twice. The supernatant was transferred and centri-
fuged at 7000 g for 10 min.
Mitochondrial function assay
OCR and ECAR were monitored using an XFp analyzer
(Seahorse Bioscience, North Billerica, MA, USA) and
XFp cell mito-stress test kit (Seahorse Bioscience). 3 ×
103 cells were seeded in XFp cell culture miniplate and
growth media were replaced with XFp assay media 1 h
before the test. All the reagents and assay conditions
were followed by manufacturer’s instructions.
Flow cytometry analysis
For cell cycle analysis, cells were fixed in 70% ethanol over-
night, washed twice with PBS and suspended in staining
buffer (0.1% Triton X-100, 0.2 mg/ml RNase A, 1 μg/ml
Propidium iodide(PI) in PBS) for 10 min. For apoptosis de-
tection, cells were trypsinized, washed with PBS and stained
with PI and annexin V in binding buffer (10 mM HEPES,
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) for 15 min. The
stained cells were washed twice with PBS and analyzed by
FACS caliber (BD science, Franklin Lakes, NJ, USA).
Statistical analyses
Data are presented as mean ± S.D. or S.E. Student’s t-test
was used to analyze differences between experimental
groups. Values of *p < 0.05 or **p < 0.01 or ***p < 0.005
were considered significant.
Results
GPR119 expression in human breast cancer cells and
tumor tissues
We found GEO datasets containing GPR119 transcript
levels in various cancer cell types (Fig. 1a, upper panel). Al-
though significant differences were not seen between be-
nign and malignant cancer tissues, GPR119 mRNA was
identified from human breast cancer tissue datasets (Fig.
1a). By public dataset analysis, GPR119 mRNA was not as-
sociated with cancer metastasis or pathology classification
of breast cancer (Fig. 1a, lower panels). We further quanti-
fied GPR119 mRNA expression in 11 breast cancer cell
lines and MCF10A mammary epithelial cell line by
real-time qPCR analyses. Compared to MCF-10A, GPR119
mRNA was amplified in seven breast cancer cell lines, and
there were no correlation between existence of hormone
receptors or Her2 and GPR119 exprtession (Fig. 1b).
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Fig. 1 (See legend on next page.)
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Immunohistochemistry showed that 19 samples from 49
human breast cancer tissues were GPR119 positive, but
there were no remarkable changes in GPR119 expression
depending on TMN stages and tumor stages of patients or
estrogen receptor (ER)-α (Table 1). Thus, GPR119 was con-
stitutively expressed in human breast cancer.
Proliferation inhibition and intrinsic apoptosis by GPR119
agonist in breast cancer cells
Aberrant EGFR signaling is involved in poor prognosis of
many types of cancer. One of the current treatment options
for breast cancer is EGFR-TKI as well as anti-hormone
agents [19]. However, clinical outcomes of EGFR-TKI are
less successful than expected [20]. Hence, we assessed
whether GPR119 agonist provides synergistic benefit with
EGFR-TKI in human breast cancer. To assess the potential
synergism of two drugs, ‘isobole model’ has been frequently
used [21]. In the isobole model, the position of coordinates
of drug doses displayed the effect of combination (additive,
synergistic, antagonistic effect). The IC50 values of gefitinib
and MBX-22982 in cell proliferation of MCF-7 cells (a
representative ER+ breast cancer cell line) were 21.2 μM
and 18.8 μM, respectively. The dose pairs of the combin-
ation of gefitinib and MBX-2982 were below the isobole in-
dicating the synergistic effect of the drug combination
(Fig. 2a). We also calculated the isobologram of the drug
combination on MDA-MB-231 cells [a triple negative
breast cancer (TNBC) cell line] and observed the same
results (Fig. 2b). Another GPR119 agonist used in clinical
trials, GSK1292263, also potentiated the anti-proliferative
effect of gefitinib on MCF-7 and MDA-MB-231 cells
(Additional file 1: Figure S1A and B). We further tested the
combined effects of GPR119 agonist with gefitinib on cell
proliferation of MDA-MB-468 (a TNBC cell line) and
SK-BR-3 cells (a Her2+ and ER+ breast cancer cell line).
Cotreatment with 3 μM MBX-2982 and 100 nM gefitinib
additively suppressed cell proliferation of MDA-MB-468 or
SK-BR-3 cells (Additional file 1: Figure S1C). The data
suggest that GPR119 aognist with gefitinib synergistically
inhibits proliferation of breast cancer cells.
We then assessed the effect of OEA (endogenous
GPR119 ligand) on proliferation of MCF-7 cells. Because
EC50 values of MBX-2982 and OEA for GPR119 are
3.9 nM and 0.2–5 μM, respectively [22], pharmacological
potency of MBX-2982 is 51.3–1282.1 fold higher than
OEA. When we assessed cell proliferation inhibitory effect
of OEA (10 mM) in MCF-7 cells, the compound did not
change the basal cell growth (Additional file 1: Figure S1D).
However, co-treatment with OEA and gefitinib significantly
reduced cell proliferation of MCF-7 cells compared to gefi-
tinib alone group (Additional file 1: Figure S1D).
To examine a possible mechanism for the anti-cancer ef-
fects of GPR119 agonists, flow cytometry analyses were per-
formed after exposure of MCF-7 cells to MBX-2982 for
48 h. Annexin V and propidium iodide (PI) staining revealed
that a late-apoptotic population was 6.9-fold enhanced in a
MBX-2982-gefitinib cotreated group compared to the
gefitinib-alone group (Fig. 2c). Representative apoptosis indi-
ces, caspase3/7 activity and poly (ADP-ribose) polymerase
(PARP) cleavage also increased with cotreatment for 36 h
(Fig. 2d and e). The relative ratio of Bcl-2/Bax expresion rep-
resents intrinsic apoptosis marker, and caspase-8 activation
is related with extrinsic apoptosis pathway [23]. Although
Bax expression was not altered, Bcl-2 expression was de-
creased by cotreatment with MBX-2982/gefitinib (Fig. 2f).
Changes in cleaved caspase-8 (active form) were not ob-
served in all treatment groups (Fig. 2g). We further analyzed
cell cycle progression and the expression of cell cycle marker
proteins. Cell population percentage of S phase was
(See figure on previous page.)
Fig. 1 GPR119 expression in human breast cancer cells and tumor tissues. a Gene Expression Omnibus profiles of GPR119 in human breast
cancer. Upper, relative mRNA levels of GPR119 in human cancer cell lines; lower, GPR119 mRNA expression in metastatic and primary breast
cancer tissues; GPR119 mRNA expression in triple negative breast cancer (TNBC) and Non-TNBC tissues. b Expression levels of GPR119 mRNA in
various human breast cancer cell lines were verified by real-time qPCR. MCF10A cells were used as normal mammary epithelial cells
Table 1 Correlation between GPR119 expression and
pathological parameters of breast cancer patients



















ER alpha (IHC) 0.0898
Negative 9 4
Positive 21 15
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significantly reduced by co-treatment with gefitinib and
MBX-2982, and p27 expression was also remarkably sup-
pressed (Fig. 2h and i). These results indicate that the
anti-proliferative effect of GPR119 agonist seemed to be re-
lated with impairment of cell cycle progression as well as
stimulation of late apoptosis.
Inhibition of EGFR-TKI-induced autophagy by MBX-2982
in breast cancer cells
Autophagy process triggered by autophagosome formation
shows dual functions; cell survival and cell death. Chemo-
therapies including EGFR-TKI induce functional autophagy




F G H I
D E
Fig. 2 Enhanced proliferation inhibition by GPR119 agonists in breast cancer cells. a and b Synergistic effects of GPR119 agonist on cell proliferation
inhibition by gefitinib in MCF-7 a and MDA-MB-231 cells b. Isobole model was used to evaluate drug combination effect. c Apoptosis induction by
gefitinib with MBX-2982. Apoptosis was determined by PI and annexin V staining. The stained cells were analyzed by flow cytometry in MCF-7 cells.
Annexin V-positive pro-apoptotic and late-apoptotic cells were counted by BD CellQuest Pro software. d Caspase3/7 activity. MCF-7 cells were
preincubated with DEVD-NucViewTM 488, and exposed to gefitinib and MBX-2982 for 60 h, and caspase-3/7-selective green fluorescence was monitored.
Green fluorescence intensity was calculated by Incucyte® ZOOM basic analyzer. e PARP cleavage by gefitinib with MBX-2982. MCF-7 cells were incubated
in the presence of gefitinib or gefitinib with MBX-2982 for 48 h. Western blot analyses were performed to determine PARP cleavage. f Expression of Bcl-2
and Bax. g Expression of cleaved caspase-8 (active form). MCF-7 cells were incubated with 10 μM gefitinib, 10 μM MBX or gefitinib/MBX for 24 h. Cell cycle
analysis h and cell cycle-associated protein expression i. MCF-7 cells were treated with MBX-2982 (MBX) for 24 h and fixed with ethanol. Cell cycle was
analyzed by propidium iodide (PI) staining in MCF-7 cells. For the quantification of protein expression of p53, p21 and p27, MCF-7 cells were incubated
with 1-10 μM MBX-2982 for 24 h. Data represent the mean ± S.D. (n=3). ** p < 0.01, *** p < 0.005 significant difference versus control group
Im et al. Journal of Experimental & Clinical Cancer Research          (2018) 37:295 Page 6 of 15
induces autophagy in breast cancer cells, we determined
LC3B II expression as a marker of autophagosome forma-
tion [25]. LC3B II protein increased with gefitinib treatment
in MCF-7 and MDA-MB-231 cells (Fig. 3a). Transmission
electron microscopy (TEM) showed that a lipid bilayer
structure in the cytoplasm (autophagosomes) formed in
MCF-7 cells with gefitinib treatment (Fig. 3b). When ATG7
was silenced by siRNA transfection to block autophagy,
gefitinib-induced inhibition of cell proliferation was poten-
tiated (Fig. 3c), suggesting that gefitinib-induced autophagy
is a survival mechanism of cancer cells.
Gefitinib-induced LC3B II expression was suppressed in
MCF-7 and MDA-MB-231 cells by MBX-2982 (Fig. 3d).
GSK1292263 also inhibited conversion to LC3B II in
response to gefitinib (Fig. 3e). Chloroquine, a blocker of
autophagolysosome formation, accumulates autophago-
somes in cells [25]. We confirmed these results using
MCF-7 cells transfected with a green fluorescence protein
(GFP)-tagged LC3B overexpression plasmid. GFP fluores-
cence was ubiquitous in whole cells after vehicle treatment,
while green punctuate structures were observed in
gefitinib-treated MCF-7 cells, and the number of GFP
puncta was diminished by MBX-2982 treatment (Fig. 3f,
left). In LC3B puncta formation assays with red
fluorescence protein (mCherry) tagging, the number
of puncta significantly decreased with MBX-2982
treatment (Fig. 3f, right). We then tested the effects
of MBX-2982 on tumor growth of xenograft implants
of MCF-7 cells. Because MCF-7 cells show
hormone-dependent growth, 17-β-estrogen (2 mg/kg/
day) was subcutaneously injected into tumor-bearing
mice. Tumor growth was moderately reduced by oral
administration of gefitinib, whereas tumor growth was
completely suppressed by co-administration of gefi-
tinib with MBX-2982 (Fig. 3g). The data demonstrate
that GPR119 agonist inhibits autophagosome forma-
tion in cancer cells treated with EGFR-TKI and pos-
sess anticancer effects against breast cancer.
Cell proliferation inhibition by GPR119 agonist and target
chemotherapies
We further tested synergistic effects of GPR119 agonist
with other target therapeuctic agents, tamoxifen and soraf-
enib. Tamoxifen is a selective estrogen receptor modulator
and is widely used to treat or prevent estrogen
receptor-positive breast cancer [26]. Cell proliferation of
MCF-7 cells was partially inhibited by 0.3–10 μM
4-hydroxytamoxifen (4-OHT), an active metabolite of tam-
oxifen, but concentration-dependency was not observed
(Fig. 4a). Whereas, combination of 0.3 μM 4-OHT with
MBX-2982 or GSK1292263 additively inhibited cell prolif-
eration of MCF-7 cells (Fig. 4b and c). Moreover,
4-OHT-induced LC3B II expression was reversed by
MBX-2982 co-treatment (Fig. 4d).
Sorafenib as a multi-kinase inhibitor is now used for the
treatment of hepatocellular carcinoma [27]. When we de-
termined GPR119 mRNA expression in HepG2, SNU-449
and SK-Hep1 hepatocellular carcinoma cell lines, GPR119
mRNA was similarly detected in HepG2 and SNU-449
cells, but its expression level was relatively low in SK-Hep1
cells (Fig. 4e). We also found that cell proliferation of
HepG2 cells, a human hepatoma cell line was additively
inhibited by the combination of sorafenib with MBX-2982
(Fig. 4f). In a similar pattern to MCF-7 cells treated with
gefitinib, LC3B II expression was increased in HepG2 cells
exposed to sorafenib (Fig. 4g), and inhibitory effect of soraf-
enib on cell proliferation was potentiated by ATG7 siRNA
transfection (Fig. 4h). Moreover, sorafenib-induced LC3B II
expression was inhibited by MBX-2982 in HepG2 cells
(Fig. 4i), and apoptotic markers such as cleaved forms of
caspase-3 and PARP were enhanced by cotreatment with
sorafenib and MBX-2982 in HepG2 cells (Fig. 4j). We also
tested the in vivo effects of MBX-2982 on xenograft im-
plants of HepG2-X cells, a HepG2 subclone for xenograft.
Co-administration of MBX-2982 with sorafenib synergis-
tically inhibited tumor growth of HepG2-X cells (Fig. 4k).
These results indicate that cancer cells induce au-
tophagy in response to target therapies as a survival
mechanism and GPR119 agonist possesses anticancer
effects via autophagy inhibition.
GPR119 signaling in autophagy inhibition by MBX-2982
We established GPR119 knockdown cells by shRNA infec-
tion to assess whether autophagy inhibition by MBX-2982
was due to target receptor-mediated response. MCF-7
cells were infected with shGPR119 lentivirus and
puromycin-resistant GPR119 knockout clones of MCF-7
cells were selected. GPR119 mRNA was determined by
quantitative RT-PCR (Fig. 5a). MBX-2982 inhibited
gefitinib-induced LC3B II protein expression in nontar-
geted shRNA-infected MCF-7 cells. GPR119 knockdown
reversed the inhibition of LC3B II expression by
MBX-2982 (Fig. 5b), implying that GPR119 signaling was
required for the inhibitory effect of MBX-2982. More-
over, the coadministration of gefitinib with MBX-2982
did not reduce the tumor volume in xenografts im-
planted with shGPR119-MCF-7 cells (Fig 5c), which
imply that GPR119 signaling is required for
anti-cancer effect of MBX-2982.
Stimulation of GPR119 coupled to Gαs results in
cAMP increase and protein kinase A (PKA) activation
[28]. When we determined reporter activity using a
cAMP response element (CRE) to represent intracellular
cAMP production, 10 μM MBX-2982 increased the lu-
ciferase reporter activity (Fig. 5d). However, cAMP path-
way inhibition with TK5720, a specific PKA inhibitor,
did not restore the diminished LC3B II expression by
MBX-2982 in MCF-7 cells (Fig. 5e). Because the






Fig. 3 Inhibition of gefitinib-induced autophagy by GPR119 ligands in breast cancer cells. a Autophagy induction by gefitinib in human breast cancer
cells. LC3B I/II were measured by immunoblottings in breast cancer cells (MCF-7 and MDA-MB-231 cells). Cells were incubated with 1-30 μM gefitinib
for 24 h. b Autophagosome formations in gefitinib-treated MCF-7. Autophagosome formation was visualized by TEM in MCF-7 cells. Cells were
incubated with 10 μM gefitinib for 24 h. Star marks indicate double lipid layer vesicle structures. c Effect of ATG7 siRNA on anti-proliferative effect of
gefitinib. ATG7 expression was detected by western blotting after siATG7 transfection (upper) and cell proliferation was monitored by Incucyte® ZOOM
basic analyzer in MCF-7 cells (lower). Data represent the mean ± S.D. (n=6). d Inhibition of gefitinib-induced autophagy formation by MBX-2982 (MBX).
LC3B I/II were measured by western blottings in breast cancer cells incubated with 10 μM gefitinib in the presence or absence of 1-10 μM MBX or 3
μM chloroquine. e Inhibition of gefitinib-induced autophagy formation by GSK1292263 (GSK). LC3B I/II were measured by western blottings in MCF-7
cells incubated with 10 μM gefitinib, 10 μM MBX, 10 μM GSK or 3 μM chloroquine for 24 h. f Inhibition of autophagosome puncture formation by
MBX. Green fluorescence puncta were detected by fluorescence microscopy after LC3-GFP transfection in MCF-7 cells (left). Red fluorescence was
calculated in MCF-7 cells after mCherry-GFP-LC3 plasmid transfection by Incucyte® ZOOM basic analyzer (right). MCF-7 cells were incubated with 10
μM gefitinib in the presence or absence of 10 μM MBX. Data represent the mean ± S.D. (n=3). g Tumor growth of MCF-7 xenograft was monitored for
40 days. Data represent the mean ± S.E. (n=5). * p < 0.05, significant difference between the indicated two groups
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mTORC1 pathway suppresses ULK1 which initiates
autophagosome formation, we hypothesized that
mTORC1 was activated or ULK1 was inactivated by
MBX-2982. However, downstream targets of mTORC1,
phosphorylation of ribosomal protein S6 kinase β-1
(p70S6K) and eukaryotic translation initiation factor
4E-binding protein 1 (4EBP1), were inhibited by
MBX-2982 (Fig. 5f ). In addition, ULK1 phosphorylation
increased at 24 h exposure of MCF-7 cells to MBX-2982
(Fig. 5f ). Protein components that elongate autophago-
somes, ATG5, ATG7 and ATG12 were also not signifi-








Fig. 4 Enhancement of target therapy-induced proliferation inhibition by GPR119 agonists. a Cell proliferation was monitored after treatments with
vehicle or 4-OHT (0.3-10 μM). b and c Cell proliferation was monitored after treatments with 0.3 μM 4-OHT and GPR119 agonists (1-10 μM). Data
represent the mean ± S.D. (n=6). d LC3B I/II were measured by western blottings in breast cancer cells incubated with 0.3 μM 4-OHT in the presence
or absence of 10 μM MBX for 24 h. e Expression levels of GPR119 mRNA in three human hepatocellular carcinoma cell lines were verified by real-time
qPCR. f HepG2 cells were incubated with 10 μM sorafenib or MBX (1-10 μM) for 48 h, and cell proliferation was monitored by MTT assays. Data
represent the mean ± S.D. (n=6). g Autophagy induction by sorafenib in HepG2 cells. The cells were incubated with vehicle or sorafenib (1-30 μM) for
18 h. h ATG7 expression was detected by western blotting after siATG7 transfection (left) and cell proliferation was monitored by Incucyte® ZOOM
basic analyzer in HepG2 cells (right). Data represent the mean ± S.D. (n=6). i LC3B I/II were measured by western blottings in HepG2 cells incubated
with 10 μM sorafemib in the presence or absence of MBX (3 and 10 μM) or 3 μM chloroquine for 18 h. j Cells were incubated with sorafenib in the
presence or absence of MBX (1-10 μM) for 24 h. k In vivo effect of MBX-2982 on tumor growth of HepG2-X xenograft. Sorafenib (10 mg/kg), MBX-2982
(10 mg/kg) or Sorafenib with MBX-2982 were orally administered (5 times a week) and tumor growth was monitored for 18 days. Data represent the
mean ± S.E. (n=6). * p < 0.05, *** p < 0.005, significant difference between the two indicated groups
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that autophagy inhibition by GPR119 agonist is not me-
diated through classical GPR119 signaling or the PI3K/
mTORC1/ULK1 pathway.
Metabolic shift by MBX-2982 and inhibition of
gefitinib-induced autophagy by lactate
We previously reported that MBX-2982 activated
AMP-activated protein kinase (AMPK), and pleiotrophic
roles of AMPK have been investigated in many types of
cancer [22, 29]. Hence, we further investigated a potential
role of AMPK in autophagy inhibition by GPR119 agonist.
We found that AMPK was activated in MCF-7 cells by
MBX-2982, as evidenced by phosphorylation of AMPK or
acetyl CoA carboxylase (ACC), a downstream target of
AMPK (Fig. 6a), but the activation of upstream kinases
such as liver kinase B1 (LKB1) and transforming growth
factor-β-activating kinase 1 (TAK1), was not observed (data
not shown). On the other hand, cellular ATP production
was sustainedly dimished by MBX-2982 in MCF-7 cells
(Fig. 6b). Because ATP production mainly relies on mito-
chondrial oxidative phosphorylation (OXPHOS) [29], we
hypothesized that mitochondrial function might be
defective in MBX-2982 treated cells. Mitostress assays re-
vealed that exposure of MCF-7 cells to MBX-2982 or
GSK1292263 for 30 min, 2 or 6 h continuously suppressed
oxygen consumption rate (OCR), which reflects ATP pro-
duction capacity in mitochondria (Fig. 6c, left). Elevated
extracellular acidification rate (ECAR) indicates that en-
ergy metabolism inclines toward glycolysis. Both the
GPR119 agonists increased ECAR in MCF-7 cells (Fig. 6c,
right). We then assessed the effects of 2-deoxlyglucose
(2-DG), a competitive inhibitor of glycolysis. 2-DG re-
stored the elevated ECAR without OCR change in
MBX-2982-treated MCF-7 cells (Fig. 6d). Lactate is pro-
duced by lactate dehydrogenase A (LDHA) during the
process of glycolysis. GSK2387808, a LDH inhibitor, also
suppressed MBX-2982-mediated increases in ECAR with-
out changing OCR (Fig. 6e). These results domonstrate
that GPR119 agonsits cause a metabolic shift toward gly-
colysis in MCF-7 cells.
To further investigate the role of enhanced glycolysis
by GPR119 agonists, we determined intracellular and
extracellular levels of lactate, an end product of glycoly-
sis. Extracellular and intracellular levels of lactate were
A
D E F G
B C
Fig. 5 GPR119 signaling in autophagy inhibition by MBX-2982. a GPR119 mRNA expression in GPR119 shRNA-infected cells. MCF-7 cells were
infected with shGPR119 or shNonTarget lentivirus particle, and GPR119 mRNA expression was determined by real-time qPCR. Data represent the
mean ± S.D. (n = 3)(*** p < 0.005, significant difference versus shNonTarget-infected control). b Reversal of MBX-2982 (MBX)-induced autophagy
inhibition in GPR119 knock-down cells. LC3B I/II were measured by western blotting in shGPR119 or shNonTarget-infected MCF-7 cells. c
Xenograft analysis. Tumor growth of shGPR119-MCF-7 xenograft was monitored for 41 days. Balb/c-nu mice were orally administered with
gefitinib (1 mg/kg), MBX (10 mg/kg) or gefitinib with MBX (5 times a week). Data represent the mean ± S.E. (n = 3). d CRE reporter activity. MCF-7
cells were transiently transfected with CRE-luciferase reporter plasmid (CRE-luc) and its reporter activity was measured using luminometer. 10 μM
forskolin, an adenylyl cyclase activator, was used as positive control. Data represent the mean ± S.D. (n = 3)(* p < 0.05, ** p < 0.01, significant
difference versus control group). e Effect of PKA inhibitor on autophagy inhibition by MBX. MCF-7 cells were preincubated with 10 μM of TK5720,
a PKA inhibitor for 30 min and then treated with 3 μM chloroquine in the presence or absence of 10 μM MBX. f Effect of MBX on mTOR
signaling pathway. mTOR signaling pathway was estimated by immunoblottings for phosphorylated p70S6 kinase, phosphorylated 4EBP1 and
phosphorylated ULK1 in MCF-7 cells incubated with 10 μM MBX-2982 for 24 h. g Effects of MBX on the protein levels of ATG5, ATG7 and ATG12.
MCF-7 cells were incubated with MBX (1–10 μM) for 24 h
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~ 1.8-fold increased by MBX-2982, and lactate in media
even reached 20 mM (Fig. 6f, left). In shGPR119-MCF-7
cells, increased lactate by MBX-2982 was not detected
(Fig. 6f, right). We also found that lactate levels in either
cell lysates or culture media also increased by
MBX-2982 in MCF-7 cells treated with gefitnib, while
intracellular amd extracellular glucose contents were
slightly decreased (Fig. 6g). To clarify the effects of
MBX-2982 in cellular pathways of lactate production,
protein levels for MCT1/2, influx transporters of lactate
and MCT4, an efflux transporter of lactate, were quanti-
fied. Expression of the transporters did not change with
MBX-2982 (Fig. 6h). LDHA protein and enzyme activity
were not altered by MBX-2982 (Fig. 6i and j). LDHB,
which catalyzes conversion of lactate to pyruvate, was
not detected in MCF-7 cells (Fig. 6i).
We then tested whether lactate production is involved in
autophagy inhibition by MBX-2982. Given the detected
concentration of lactate in culture media (Fig. 6f), 2.5–
20 mM lactate was cotreated with gefitinib in MCF-7 cells.
Interestingly, the LC3B II expression induced by geifinib
was inhibited by 20 mM lactate (Fig. 6k). We further ascer-
tained that co-incubation of MCF-7 cells with 10–20 mM
lactate and gefitinib synergistically increased caspase-3/7
activity (Fig 6l). Thus, GPR119 agonist-mediated lactate
production may lead to autophagy inhibition and potenti-
ated cancer cell apoptosis with EGFR-TKI.
Discussion
Chemotherapy resistance frequently occurs in cancer pa-
tients and thereby restricts the clinical benefit of the che-
motherapeutic agents. The acquired resistance could be
cured by the combination with other drugs that discard the
resistance mechanism. For example, colorectal cancer har-
boring KRAS mutation shows the resistance to cetuximab,
an EGFR monoclonal antibody. Mitogen-activated protein
kinase kinase (MEK) inhibitor could increase the effect of
cetuximab through blocking Ras-Raf pathway [30]. Because
fulvestrant (pure estrogen receptor antagonist)-resistant
breast cancer frequently shows the upregulation of mTOR
pathway, the combination of fulvestrant and mTOR inhibi-
tor is more efficious than fulvestrant alone [31]. Autophagy
progression is known to be associated with cancer cell sur-
vival mechanism in the target therapies [32]. In fact, au-
tophagy inhibitors such as chloroquine and bafilomycin A
are cytotoxic to cancer cells [33], and several ongoing clin-
ical trials are using chloroquine alone or the combination
of chloroquine with taxane in breast cancer patients (Clini-
calTrials.gov Identifier: NCT02333890 and NCT01446016).
GPR119 activation stimulates insulin and GLP-1 secre-
tion in the pancreas and gastrointestinal tract and both
the activities are related to Gαs protein-dependent cAMP
secretion [34]. In addition, GPR119 expression is upregu-
lated by oxidized low-density lipoprotein in THP-1 human
monocyte cell line, and GPR119 overexpression inhibits
the development of atherosclerosis in apoE-null mice [35].
It has been shown that some GPCRs are involved in the
regulation of autophagy, thus the ligand of these GPCRs
are possible to use for autophagy-related diseases [36]. We
observed that GPR119 expressed in human breast cancer
cell lines and tumor tissues, and GPR119 agonists with ge-
fitinib additively suppressed the growth of breast cancer
cells and induced intrinsic apoptosis. Moreover, combin-
ation of GPR119 agonist with 4-hydroxytamoxifen in
MCF-7 cells as well as with sorafenib in HepG2 cells en-
hanced the anti-cancer effect of each target therapy. Al-
though GPR119 agonist did not affect cell cycle
progression in MCF-7 cells, EGFR TKI-mediated autoph-
agy stimulation was reversed by MBX-2982 treatment.
Thus, the anti-autophagy effect of GPR119 ligand may not
be specific for cancer cell types or TKI classification.
Here, we also found that mTORC1 signaling was sup-
pressed by GPR119 agonist, which is evidenced by de-
creased phosphorylations of p70S6K and 4EBP1 by
MBX-2982 in MCF-7 cells. Because the activation of
p70S6K and 4EBP1 is important for mRNA translation
[37], GPR119 agonsit-induced mTORC1 inhibition may
lead to the depletion of protein synthesis in cancer cells.
Moreover, autophagy supplies recycling nutrients such as
amino acids, nucleotides and fatty acids through the
(See figure on previous page.)
Fig. 6 Metabolic shift by MBX-2982 and inhibition of gefitinib-induced autophagy by lactate. a AMPK activity was determined by immunoblottings for
phosphorylated AMPK and phosphorylated ACC proteins in MCF-7 cells treated with 10 μM MBX-2982. b ATP content was determined by ATP assay
kit in MCF-7 cells. Cells were treated with MBX-2982 (1-10 μM). c Effects of GPR119 agonists on mitochondrial OXPHOS and glycolysis in MCF-7 cells.
d MCF-7 cells were pretreated with or without 2-deoxyglucose (2-DG, 50 mM) for 30 min and incubated with 10 μM MBX. e MCF-7 cells were
pretreated with or without GSK2837808 (LDH inhibitor, 10 μM) for 30 min and incubated with 10 μM MBX. f MBX-induced lactate production in MCF-7
(left) and shGPR119-MCF-7 cells (right). Lactate concentration was assessed by 1H-NMR or lactate assay kit in total cell lysates and culture media.
g MCF-7 cells were incubated with 10 μM gefitinib in the presence or absence of MBX for 24 h and concentrations of glucose and lactate were
determined by 1H-NMR in total cell lysates (left) and culture media (right). h and i MCF-7 cells were treated with MBX for 24 h and protein expression
of lactate transporters and lactate converting enzymes were measured by western blottings. j MCF-7 cells were treated with MBX-2982 for 24 h and
LDHA activity was determined by LDH assay kit. k MCF-7 cells were incubated with 10 μM gefitinib in the presence or absence of lactate (2.5-20 mM)
for 24 h, and LC3B I/II were measured by immunoblottings. l Caspase3/7 activation by gefitinib with lactate. MCF-7 cells were treated gefitinib (10 μM)
with or without lactate (5-20 mM) for 72 h. Data represent the mean ± S.D. (n=3). * p < 0.05, ** p < 0.01,*** p < 0.005 significanct difference between
the two indicated groups
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degradation of intracellular substrates [38]. Metabolites
analysis using LC/Ms./Ms. showed that many animo acids
as well as nucleotides were dimished by MBX-2982 treat-
ment in MCF-7 cells (Additional file 2: Figure S2). These
results support a notion that GPR119 stimulation in cancer
cells results in the deficiency of building blocks for proteins.
Apoptosis induction and autophagy inhibition by a
GPR119 agonist might be related to changes in cancer cell
metabolism instead of canonical signaling pathway(s) of
GRP119. Inhibition of autophagy by MBX-2982 was not
restored by cAMP/PKA inhibitor. Instead, our data dem-
onstrated that MBX-2982 suppressed mitochondrial
OXPHOS with increased lactate production by glycolysis
stimulation. Although future study is needed on why re-
duced OXPHOS and enhanced glycolysis occur at the
same time, intracellular ATP production was eventually
decreased by MBX-2982. We suggest that increased lac-
tate production is the cause of autophagy inhibition by
MBX-2982. The molecular mechanism for the suppres-
sion of autophagosome formation by lactate remains un-
clear, but may be associated with intracellular pH changes.
Although autophagolysosome activity is likely to be ampli-
fied by physiologically acidic pH (< 6.4) [39], GPR119
agonist-induced supraphysiological lactate production
could suppress autophagosome formation and eventually
induce cancer cell death. Intracellular pH regulation via
MCTs or LDHs could be important for cancer cell sur-
vival. Indeed, inhibitors of MCTs or LDHs are a potential
therapeutic target in cancer [40]. Another possibility is
that specific lactate receptor(s) may be involved in autop-
hagosome suppression by lactic acid.
GPR81 is activated by extracellular lactate [41–44].
GPR81 is involved in the lipolysis inhibition in adipocytes
and in the anti-inflammation in macrophages [41, 42].
Moreover, GPR81 is upregulated in malignant cancers and
involved in cell migration and metastasis [44]. Shen et al.
have shown that extracellular lactate induces
caspase-3-dependent apoptosis through Bax upregulation
in GPR81-transfected N2A (mouse neuroblastoma) cells
[43]. However, when GPR81 was depleted in MCF-7 cells
(Additional file 3: Figure S3A), MBX-2982-mediated au-
tophagy inhibition was not altered (Additional file 3: Figure
S3B), indicating that GPR81 may not be associated with
lactate-induced autophagy inhibition. From the view of
tumor microenvironment, infiltrated macrophages and as-
sociated stromal cells promote tumor progression [45].
Tumor-associated macrophages exacerbate tumor progres-
sion via the secretion of several cytokines such as
interleukin-1β and interleukin-6 [45, 46]. GPR119
agonist-mediated lactate production could suppress the
inflammatory immune cells producing tumor-promoting
cytokines via GPR81 activation. In support of this notion,
robust interleukin-1β and interleukin-6 production were
observed in macrophage from GPR81-null mice [41].
The Yeom research group first identified N-myc
downstream-regulated gene 3 protein (NDRG3) as a novel
binding partner of intracellular lactate [47]. NDRG3 protein
bound to lactate is upregulated by enhanced protein stabil-
ity and accelerates cell growth and angiogenesis of cancer
cells by activating the Raf-extracellular signal-regulated kin-
ase pathway [47]. However, NDRG3 protein expression was
not detected in MCF-7 cells exposed to MBX-2982 (Add-
itional file 3: Figure S3C). Hence, autophagy inhibition by
GPR119 agonist may not be associated with
GPR81-dependent signaling by extracellular lactate or
NDRG3-dependent signaling by intracellular lactate.
Because a previous study has reported that increased gly-
colysis and lactate production triggers breast cancer cell
stemness and tumor growth in MCF-7 cells [48], GPR119
activation could be related with cancer cell stemness. To as-
sess whether GPR119 agonist induces cancer cell stemness
in MCF-7 cells, we performed spheroid formation assay in
ultra-low attachment (ULA) plate condition. 103 MCF-7
cells cultured on ULA plate were incubated with vehicle or
GPR119 agonist for 96 h. Interestingly, the spheroid volume
was significantly diminished by MBX-2982 (Additional
file 3: Figure S3D), which suggest that GPR119 agonist does
not induce cancer cell stemness, rather inhibits spheroid
formation. Martinez-Outschoorn et al. also described that
metformin exerts its anti-cancer effects via inducing aerobic
glycolysis that has been proposed as a cause of cancer [48].
Hence, the revaluation of glycolysis and lactate production
on the cancer cell stemness would be required.
The inhibition of mitochondrial OXPHOS by MBX-2982
appeared to be partially related to a direct action of GPR119
agonist on mitochondria. When we examined mitochondrial
stress in GPR119-knockdown MCF-7 cells, GRP119 receptor
depletion significantly restored mitochondrial stress (OCR
decrease) induced by 3 μM MBX-2982. However, OCR de-
crease was not restored in GPR119 knockdown cells
incubated with 10 μM MBX-2982 (Additional file 4: Fig.
S4A). Considering our finding that high concentration of
MBX-2982 inhibited OCR in receptor-independent manner,
we tested the direct effect of MBX-2982 on mitochondrial
complex activity. We found that 10− 10–10− 6 M MBX-2982
marginally inhibited the enzyme activity of complex I in iso-
lated mitochondria (Additional file 4: Figure S4B). After 3 h
incubation of MCF-7 cells with 10 μM MBX-2982, approxi-
mately 10% of MBX-2982 was detected in a mitochondrial
fraction compared to the amount in whole cell lysates, using
LC/Ms./Ms. analysis (Additional file 4: Figure S4C). Hence, a
MBX-2982-induced metabolic shift in cancer cells may result
from a direct action on mitochondria as well as GPR119
receptor-dependent activity. It has been suggested that sev-
eral mitochondrial targeting agents could be adopted for
cancer chemotherapies. CPI-613, an α-linolic acid derivative,
selectively targets altered mitochondrial function and induces
cell death in H460 lung cancer cells [49]. Metformin, an
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AMPK activator, inhibits complex I and is used to treat di-
verse types of cancer in clinical trials [50].
Conclusion
GPR119 agonists reduced mitochondrial OXPHOS and
stimulated glycolysis in breast cancer cells, with consequent
overproduction of lactate that inhibited autophagosome
formation. Because autophagy is crucial for the survival of
cancer cells exposed to TKIs, GPR119 agonists potentiated
the anticancer effects of TKIs. Our findings indicate that
the combination of GPR119 agonist with TKI would be a
possible therapeutic approach for cancer chemotherapy.
Additional files
Additional file 1: Figure S1. Additive effects of GPR119 agonists on cell
proliferation inhibition by gefitinib in breast cancer cell lines. (A, B) Additive
effect of GSK1292263 (GSK) on cell proliferation inhibition by gefitinib in
MCF-7 (A) and MDA-MB-231 cells. MCF-7 and MDA-MB-231 cells were
treated with 10 μM gefitinib and 1–10 μM GSK (left), or GSK alone (right). (C)
Additive effects of MBX-2982 (MBX) on cell proliferation inhibition by gefi-
tinib in SK-BR-3 and MDA-MB-468 cells. (D) Combined effect of gefitinib with
oleoylethanolamine (OEA) on cell proliferation of MCF-7 cells. The cells were
incubated with 10 μM gefitinib in the presence or absence of 10 mM OEA.
Relative proliferation rate was calculated by Incucyte® ZOOM basic analyzer.
Data represent the mean ± S.D. (n = 6)(*** p < 0.005, significant difference
between the indicated two groups). (PDF 119 kb)
Additional file 2: Figure S2. Identification of cellular metabolites with
significant differences (p < 0.05) in MBX-2982-treated MCF-7 cells. MCF-7
cells were treated with 10 μM MBX-2982 for 24 h, and the relative cellular
contents of metabolites were determined by LC/Ms./Ms. Data represent
the mean ± S.D. (n = 3). (PDF 118 kb)
Additional file 3: Figure S3. Roles of GPR81 and NDRG3 in autophagy
inhibition by MBX-2982. (A) GPR81 mRNA expression in GPR81 shRNA-infected
cells. MCF-7 cells were infected with shGPR81 or shNonTarget
lentivirus particle, and GPR81 mRNA expression was determined by real-time
qPCR. Data represent the mean ± S.D. (n = 3)(*** p< 0.005, significant
difference versus shNonTarget infected control). (B) Effect of GPR81 shRNA on
autophagy inhibition by MBX-2982. LC3B I/II were determined by
immunoblotting in shRNA control or shGPR81-infected MCF-7 cells. Both the
cells were treated with 10 μM gefitinib in the presence or absence of 10 μM
MBX-2982 for 24 h. Data represent the mean ± S.D. (n = 3)(* p< 0.05,
significant difference between the indicated two groups). (C) Protein
expression of NDRG3 (intracellular lactate receptor). MCF-7 cells were treated
with 10 μM gefitinib in the presence or absence of 10 μM MBX-2982 for 24 h,
and proten level of NDRG3 was monitored by immunoblotting. (D) Spheroid
formation assay. 103 MCF-7 cells were incubated with 10 μM gefitinib and/or
10 μM MBX-2982 for 96 h on ULA plate. Left, Representative spheroid images.
Right, Spheroid volume. Data represent the mean± S.D. (n = 3)(** p < 0.01,
significant difference between the indicated two groups). (PDF 119 kb)
Additional file 4: Figure S4. Mitochondrial distribution of MBX-2982 and
complex I inhibition. (A) GPR119-independent inhibition of OCR by 10 μM
MBX-2982. OCR and ECAR were measured by XFp analyzer in both
non-target shRNA- or GPR119 shRNA-infected MCF-7 cells. Both the cell
types were treated with MBX-2982 (1–10 μM). (B) Mitochondrial complex I
inhibition by MBX-2982. Complex I inhibition by MBX-2982 (10− 10, 10− 8 and
10− 6 M) was tested by mitostress test kit. Rotenone (100 nM) was used as a
positive control of complex I inhibition. (C) Relative amounts of MBX-2982
were determined by LC/Ms./Ms. MCF-7 cells were incubated with MBX-2982
(10 μM) for 6 h and then homogenized. Cellular component fraction was
isolated by sucrose gradient method. (PDF 107 kb)
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